Senior Editor of The Oxford Income Letter
Chief Income Strategist of The Oxford Club
Marc Lichtenfeld is the Chief Income Strategist of The Oxford Club and Senior Editor of The Oxford Income Letter, where he runs the Instant Income Portfolio, Compound Income Portfolio and Retirement Catch-Up/High Yield Portfolio. Marc is also the editor of Dividend Multiplier, Oxford Systems Trader and Lightning Trend Trader.
Prior to joining The Oxford Club, he was a sell-side analyst for the contrarian Avalon Research Group and a senior columnist for TheStreet.com. Marc is often featured on national media including WSJ.com, MarketWatch, CNBC, and National Public Radio. A featured speaker at investment conferences, he has spoken about dividend investing at meetings all over the world. Marc is also the only published financial analyst to have ring announced world championship boxing and mixed martial arts on HBO, Showtime, and ESPN.
Crowdfunding Opportunities Takeoff in 2017 w/ Private Equity Expert and Early Investing Founder, Adam Sharp
Marc’s just returned from JP Morgan’s 35th annual Healthcare Conference in San Francisco. And in this week’s episode, he’s covering all the details…from groundbreaking new medical technologies, to political sentiment, to insider meetings, and new drug announcements…Marc’s got all the exciting details. Then, he sits down with private equity expert and Early Investing Founder, Adam […]
The 2017 Bond Market Forecast w/ Oxford Club Bond Strategist Steve McDonald
Rising interest rates indicate that the Fed’s regaining confidence in the US economy. But, tightening monetary policy can have an adverse affect on fixed income investments, as rising rates hurt bond values. As a result, it’s more important than ever to understand the role of bonds in a diversified portfolio, and where you can find […]
Immunotherapy Expert, Brad Loncar, Reveals Biotech Forecast for 2017
Our nation’s top biotech insiders are gathering at JP Morgan’s 35th annual Healthcare Conference in San Francisco next week. I’ll be at the invitation-only event, which draws thousands of top fund mangers, analysts, investment bankers, and drug company CEOs together for an exclusive look at the most promising medical breakthroughs tee’d up for the coming year. […]